Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

127.99
Delayed Data
As of Aug 29
 -1.64 / -1.27%
Today’s Change
110.56
Today|||52-Week Range
193.45
-32.90%
Year-to-Date
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug 24 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for August 22nd
Aug 22 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for August 22nd
Aug 22 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close129.63
Today’s open129.59
Day’s range127.71 - 130.38
Volume955,624
Average volume (3 months)1,792,734
Market cap$29.1B
Dividend yield--
Data as of 08/29/2016

Growth & Valuation

Earnings growth (last year)-79.45%
Earnings growth (this year)-6.51%
Earnings growth (next 5 years)+24.20%
Revenue growth (last year)+12.25%
P/E ratio426.6
Price/Sales16.57
Price/Book3.54

Competitors

 Today’s
change
Today’s
% change
BAXBaxter International...+0.23+0.49%
ZTSZoetis Inc0.000.00%
VRTXVertex Pharmaceutica...-0.15-0.15%
MYLMylan NV+0.19+0.44%
Data as of 08/29/2016

Financials

Next reporting dateOctober 20, 2016
EPS forecast (this quarter)$1.19
Annual revenue (last year)$2.5B
Annual profit (last year)$144.4M
Net profit margin5.81%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David L. Hallal
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
Cheshire, Connecticut

Forecasts

Partner Offers

Search for Jobs